Metadon Nordic Drugs (Methadone Hydrochloride)

Methadone hydrochloride works by binding to mu‑opioid receptors in the brain and spinal cord, acting as a full agonist. This activation produces analgesia and reduces the physiological response to opioid withdrawal. Its additional NMDA receptor antagonism may also contribute to pain control and reduce tolerance development.

The appropriate dose of Metadon is individualized and determined by the prescribing clinician based on the patient’s medical condition, opioid tolerance, and response to therapy. Dosage adjustments are made during treatment to achieve optimal control of withdrawal symptoms or pain while minimizing adverse effects.

Safety data for methadone use in pregnancy and lactation are limited, and the medication should only be used if the potential benefits outweigh the risks. Pregnant or nursing patients must discuss treatment options with their healthcare provider, who can assess maternal and fetal considerations and monitor closely.

To request Metadon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Metadon is a long‑acting full mu‑opioid receptor agonist, offering once‑daily dosing and stable plasma levels, which can be advantageous over shorter‑acting agents like buprenorphine that act as partial agonists. Its pharmacokinetic profile may provide smoother withdrawal suppression, but individual response and safety considerations guide therapy choice.

Metadon should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Metadon is administered orally, typically as a tablet or liquid formulation, as directed by the prescribing clinician. The medication should be taken with or without food according to the healthcare provider’s instructions, and the dose may be adjusted gradually to achieve therapeutic goals.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, and cardiac arrhythmias due to QT interval prolongation. Patients should be monitored for signs of slowed breathing, dizziness, or irregular heart rhythms, and any concerning symptoms should be reported promptly.

Metadon is contraindicated in individuals with known hypersensitivity to methadone or any component of the formulation, in patients taking monoamine oxidase inhibitors, and in those with significant uncontrolled cardiac arrhythmias or severe respiratory insufficiency. Clinicians must evaluate each patient’s medical history before initiating therapy.